Role of extended adjuvant therapy in minimizing recurrence risk in HR+/HER2+ breast cancer
15 Nov 2025
byDr. Joyce Lee, Specialist in Oncology, Private Practice , Hong Kong
Pathological complete response (pCR) to earlier therapy is one of the key prognostic factors in patients with HER2-positive (HER2+) breast cancer (BC), which can help inform subsequent treatment decisions. In an interview with MIMS Oncology, Dr Joyce Lee, Specialist in Oncology in private practice in Hong Kong, discusses pCR and factors associated with disease recurrence, as well as data supporting the use of neratinib, an irreversible, small-molecule pan-HER tyrosine kinase inhibitor (TKI), as extended adjuvant therapy in hormone receptor– positive (HR+)/HER2+ BC.
